| |
|
|
|
Phacilitate Ltd, The Marriott Long Wharf Hotel, Boston, MA
14-16 November 2007
Visit www.phacilitate.co.uk/oncology for the latest program information.
|
|
|
|
|
|
|
|
Organized by:
|
|
Phacilitate Ltd |
|
|
Invited Speakers:
|
|
Visit www.phacilitate.co.uk/oncology for the full list of confirmed speakers, which includes:
- Mara G. Aspinall, President, Genetics, Genzyme Corporation
- Dr Brent M. Vose, Vice President & Head of Oncology & Infection, AstraZeneca
- Dr Peter T. C. Ho, Senior Vice President of Oncology Center of Excellence for Drug Discovery, GlaxoSmithKline
- Barry M. Straube, MD, CMS Chief Medical Officer & Director, Office of Clinical Standards & Quality, Centers for Medicare & Medicaid Services
- Kapil Dhingra, MD, Head of the Oncology Global Drug Development Group, Hoffmann-La Roche, Inc
- Dr Lawrence Shulman, Chief Medical Officer, Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute & Director, Network Development, Dana-Farber/Brigham & Women's Cancer Care
- Christopher Seaton, Senior Vice President, Global Business Development & Licensing, Bayer Corporation
- Professor Sir Michael Rawlins, Chairman, National Institute for Clinical Excellence
- Lee F. Allen, MD, PhD, Cambridge Site Head, Vice President, Medical Research - Oncology Therapeutic Area, Wyeth Research
- Dr Naomi Aronson, Executive Director, Technology Evaluation Center (TEC), BlueCross & BlueShield Association
- Steven D. Harr, Managing Director & Analyst, Morgan Stanley
- Dr Roy Baynes, Vice President, Clinical Development, Therapeutic Area Head, Oncology Supportive Care, Amgen, Inc
- Dr Stephen Kelsey, Vice President & Head of Exploratory Clinical Development, BioOncology, Genentech, Inc
- Dr Doris Slate, Vice President, Scientific Licensing, Johnson & Johnson
- Dr Nicholas C. Dracopoli, Vice President, Clinical Discovery Technologies, Bristol-Myers Squibb Pharmaceutical Research Institute
- Geert Kolvenbag, MD, PhD, Executive Director of Development, Emerging Oncology Brands, AstraZeneca
- Dr David Chang, Vice President, Global Clinical Development, Oncology Therapeutics, Amgen
- Jeffrey D. Bloss, MD, Vice President, Clinical Development, Onyx Pharmaceuticals, Inc
- Anne E. Hagey, MD, Global Project Head, Oncology Cytotoxics, Abbott Laboratories
- Thomas W. Griffin, MD, Executive Director, Therapeutic Area Head, Oncology Therapeutics, North American Medical Affairs, Amgen, Inc
- Howard J. Fingert, MD, FACP, Senior Director & Clinical Lead, Signal Transduction Development Program, Pfizer Oncology
- Dr Jay Feingold, Assistant Vice President & Multi-Therapeutic Area Head, Global Medical Affairs, Wyeth Research
- Dr Neil W. Gibson, Chief Scientific Officer, OSI Pharmaceuticals, Inc
- Dr Robert L. Ilaria Jr, Medical Advisor for Oncology, Eli Lilly and Company
- Professor James Carmichael, CMO, KuDOS Pharmaceuticals.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
Visit www.phacilitate.co.uk/oncology for information and online registration.
|
|
|
E-mail:
|
|
nicola@phacilitate.co.uk
|
|
|
|
|
|
|
|
|